The deal involves Eli Lilly, which makes Zepbound and Mounjaro, and Novo Nordisk, the maker of Ozempic and Wegovy. The drugs, known as GLP-1 medications, now cost as much as $1350 a month. Under the ...
A White House deal with Eli Lilly & Co. and Novo Nordisk to lower the prices of their popular obesity medicines, Zepbound and ...
Oral GLP-1 weight loss pills could replace injections by March 2026 at $150 monthly, Medicare chief Dr. Mehmet Oz predicted in a FOX Business appearance.
Zacks Investment Research on MSN
Will Lower GLP-1 Prices Undermine Novo Nordisk's Near-Term Outlook?
Novo Nordisk NVO is a dominant player in the cardiometabolic space, which markets its blockbuster semaglutide-based (GLP-1) ...
Audacy on MSNOpinion
Could lower prices increase demand for weight loss drugs?
Drugs like Wegovy and Ozempic have been in high demand after they were found to help in losing weight. But could a Trump ...
When a man suddenly collapsed during a televised White house event about weight-loss drugs, it sparked widespread speculation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback